Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson/P&G Macrobid “Authorized” Generic Challenged By Mylan

Executive Summary

Mylan argues an "authorized" generic agreement between Watson and Procter & Gamble for a version of Macrobid inhibits competition

You may also be interested in...



“Authorized” Generic Opponents Turn To State Laws After Federal Court Loss

Generic companies are pursuing alternative litigation routes in their efforts to block "authorized" generics following a Washington, D.C. appeals court decision upholding FDA's current policy on the products

“Authorized” Generic Opponents Turn To State Laws After Federal Court Loss

Generic companies are pursuing alternative litigation routes in their efforts to block "authorized" generics following a Washington, D.C. appeals court decision upholding FDA's current policy on the products

Mylan Challenge To “Authorized” Generics May Shift To Antitrust Arguments

Mylan could turn to antitrust laws as an avenue for renewing a court challenge against "authorized" generics after dropping its lawsuit against FDA

Related Content

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel